Genmab
GMAB
198 hedge funds and large institutions have $1.5B invested in Genmab in 2020 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 84 increasing their positions, 52 reducing their positions, and 19 closing their positions.
214% more call options, than puts
Call options by funds: $6.2M | Put options by funds: $1.98M
132% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 19
62% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 52
14% more funds holding
Funds holding: 174 → 198 (+24)
12% more capital invested
Capital invested by funds: $1.34B → $1.5B (+$159M)
4.46% more ownership
Funds ownership: 58.12% → 62.58% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$33.6M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$21.3M |
| 3 |
Renaissance Technologies
New York
|
+$20.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$18.1M |
| 5 |
Jennison Associates
New York
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$35.8M |
| 2 |
Morgan Stanley
New York
|
-$15.2M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$10.5M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$9.05M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$7.85M |
GMAB Hedge Fund Activity: Q3 2020 in Review
198 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q3 2020, worth a combined $1.5B — up 12% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new GMAB positions and 19 closed out — a net gain of 25 holders — while 84 added to existing stakes and 52 trimmed.
The largest buyer was 1832 Asset Management, adding an estimated $33.6M. The largest seller was Redmile Group, exiting entirely with an estimated $35.8M sold.
- 198 institutional investors held Genmab (GMAB) as of Q3 2020, up from 174 in Q2 2020.
- Funds reported $1.5B of Genmab stock for Q3 2020, up 12% quarter-over-quarter.
- 44 funds opened new Genmab positions in Q3 2020 and 19 closed out, a net change of +25 holders.
- The largest Genmab buyer in Q3 2020 was 1832 Asset Management, an estimated $33.6M added.
- The largest Genmab seller in Q3 2020 was Redmile Group, an estimated $35.8M sold.
Based on aggregated 13F filings for Q3 2020.